News headlines about Otonomy (NASDAQ:OTIC) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Otonomy earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4809013791141 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Otonomy (NASDAQ:OTIC) traded down $0.25 during midday trading on Friday, reaching $5.85. 330,718 shares of the company’s stock traded hands, compared to its average volume of 475,229. The stock has a market capitalization of $185.06, a price-to-earnings ratio of -1.81 and a beta of 3.33. Otonomy has a 52 week low of $2.80 and a 52 week high of $21.15.
Otonomy (NASDAQ:OTIC) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.15. The company had revenue of $0.28 million during the quarter, compared to analyst estimates of $0.43 million. Otonomy had a negative net margin of 7,899.03% and a negative return on equity of 60.74%. Otonomy’s revenue was down 12.8% compared to the same quarter last year. sell-side analysts predict that Otonomy will post -2.88 EPS for the current fiscal year.
A number of research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Otonomy from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Piper Jaffray Companies reaffirmed a “hold” rating and set a $8.00 price objective on shares of Otonomy in a research note on Friday, November 10th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the company. Otonomy currently has an average rating of “Hold” and an average price target of $9.15.
TRADEMARK VIOLATION WARNING: This story was posted by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another site, it was illegally copied and reposted in violation of international copyright laws. The original version of this story can be viewed at https://www.thestockobserver.com/2018/01/13/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-otonomy-otic-share-price.html.
Otonomy, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company’s product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase.
Receive News & Ratings for Otonomy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Otonomy and related companies with MarketBeat.com's FREE daily email newsletter.